Efficacy of mitomycin C plus a fluoropyrimidine in pretreated patients with metastatic colorectal cancer eligible to regorafenib: Results of a retrospective study.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e14661-e14661 ◽  
Author(s):  
Federica Martorana ◽  
Stefano Sergio Cordio ◽  
Roberto Bordonaro ◽  
Paolo Giovanni Vigneri ◽  
Giuseppe Novello ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Retrospective Study ◽  
Metastatic Colorectal Cancer ◽  
Mitomycin C ◽  
Pretreated Patients

scholarly journals Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study

2017 ◽  
Vol 4 (4) ◽  
pp. 456-464
Author(s):  
Federica Martorana ◽  
◽  
Paolo Vigneri ◽  
Stefano Sergio Cordio ◽  
Concetta Martines ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Retrospective Study ◽  
Metastatic Colorectal Cancer ◽  
Mitomycin C ◽  
Pretreated Patients

Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy

2020 ◽  
Vol 17 (3) ◽  
pp. 185-194
Author(s):  
Jared Freml ◽  
Thomas Delate ◽  
Jesus Hermosillo-Rodriguez
Keyword(s):  
Colorectal Cancer ◽  
Retrospective Study ◽  
Cancer Therapy ◽  
Metastatic Colorectal Cancer ◽  
Small Proportion ◽  
Biomarker Testing ◽  
Over Time

Aim: To describe pharmacogenomic tumor testing among patients with metastatic colorectal cancer. Methods: This was a retrospective study of patients with metastatic colorectal cancer diagnosed between 1 January 2014 and 30 June 2018. Patients were assessed for pharmacogenomic testing and appropriateness of chemotherapy use. Results: Overall, 112/167 (67.1%) patients had at least one of the three recommended pharmacogenomic tests and 41/167 (24.6%) had all tests. Twenty-four patients were treated with cetuximab with 8/167 (4.7%) identified as being treated with a RAS variant (n = 3) or incomplete testing (n = 5); thus, not in accordance with guidelines. Conclusion: Uptake of testing was variable but increased over time; however, a small proportion of patients received cetuximab with a variant or not all recommended tests being performed.

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer

JAMA Oncology ◽  
2021 ◽  
Author(s):  
Erika Martinelli ◽  
Giulia Martini ◽  
Vincenzo Famiglietti ◽  
Teresa Troiani ◽  
Stefania Napolitano ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Wild Type ◽  
Pretreated Patients
Sign in / Sign up

Export Citation Format

Share Document